financetom
Business
financetom
/
Business
/
Crocs Insider Sold Shares Worth $1,000,446, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crocs Insider Sold Shares Worth $1,000,446, According to a Recent SEC Filing
May 26, 2025 7:27 AM

03:23 AM EDT, 05/14/2025 (MT Newswires) -- Thomas J Smach, Director, on May 09, 2025, sold 9,139 shares in Crocs ( CROX ) for $1,000,446. Following the Form 4 filing with the SEC, Smach has control over a total of 208,591 common shares of the company, with 87,717 shares held directly and 120,874 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1334036/000133403625000058/xslF345X05/wk-form4_1747183055.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Palantir raises 2024 revenue forecast again on robust AI adoption; shares surge
Palantir raises 2024 revenue forecast again on robust AI adoption; shares surge
Nov 4, 2024
(Reuters) -Palantir Technologies on Monday raised its annual revenue forecast for the third time, betting on strong spending from governments and rising demand for its software services from businesses looking to adopt generative AI technology. Shares of the company rose about 8% in extended trading. The data analytics company has benefited from a boom in GenAI technology, as more companies...
Diamondback Energy misses estimates for third-quarter profit
Diamondback Energy misses estimates for third-quarter profit
Nov 4, 2024
Nov 4 (Reuters) - Diamondback Energy ( FANG ) missed estimates for third-quarter profit on Monday as the oil and gas firm was hurt by lower prices. The company reported an adjusted profit of $3.38 per share for the quarter ended Sept. 30, compared with analysts' average estimate of $3.98 per share, according to data compiled by LSEG. (Reporting by...
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4, 2024
(Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion, according to...
--Illumina Guides For FY 2024 Core Illumina EPS of $4.05-$4.15 on a 3% Revenue Decline
--Illumina Guides For FY 2024 Core Illumina EPS of $4.05-$4.15 on a 3% Revenue Decline
Nov 4, 2024
04:09 PM EST, 11/04/2024 (MT Newswires) -- Price: 143.00, Change: -1.03, Percent Change: -0.72 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved